FDA: Potential Low-Libido TRT Indication Pathway (Apr 2026)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: U.S. Food and Drug Administration · Published: August 21, 2026 · Accessed: August 21, 2026

Visit the source ↗

Claims this source supports

• On April 16, 2026, FDA announced an initial step to advance men's health treatment options by encouraging sponsors of approved TRT products to contact the agency if interested in pursuing a potential new indication for low libido in men with decreased libido associated with idiopathic hypogonadism.
• The announcement is a regulatory pathway invitation, not a product approval: any new indication would still require a supplemental new drug application and evidence review.
• The step formalizes what was already happening in direct-to-consumer marketing – testosterone marketed for libido – under a regulatory lens, which is why the announcement reads differently to the medical community (a pathway opening) than to marketers (validation).